CEO & Head of Investor Relations
Martin Åmark holds a M Sc. in industrial engineering and management from Linköping Institute of Technology and a MBA from INSEAD. He has 8 years of experience from Bain & Co as a management consultant. At Bain Martin worked mainly with M&A, strategy and organisation with Nordic clients across multiple industries, including life science and pharmaceuticals.
COO & Head of Biosimilars
Siavash Bashiri holds a M Sc. in Molecular Biotechnology from Uppsala University. His latest position was with Agilent Technologies where he was the head of sales in EMEA for one of Agilent Technologies’ products within the Genomics department. He also has great knowledge of the commercialization of biotech start-ups from previous experiences.
Dr. David Vikström
David Vikström is the CTO of Xbrane Bioscience. He has a Ph.D. in expression and targeting of proteins in E. coli. He joined Xbrane in 2010 and successfully developed new technologies and strains for vaccine candidates. He is currently heading the development of Xbrane’s new expression systems to be able to take the expression in E. coli to new levels.
Head of Manufacturing and Supply Chain
Anders Wallström holds a M. Sc. in Biotechnology from Royal Institute of Technology in Stockholm. He has more than 20 years of experience from process development, manufacturing and validation at SOBI and Biovitrum. Furthermore, he has significant experience from coordinating contract manufacturers for commercial products for both small molecule and biotech products.
Since September 2020
Margareta Hagman holds a Master of Business Administration from Örebro University. Active as advisor and consultant in accounting and finance. Board member of Infant Therapeutics Baby (IBT) AB and Tagmaster AB. Previously CFO and Deputy CEO of BioGaia AB.
Head of Regulatory Affairs
Maria Edebrink holds a M. Sc. in Chemistry from Stockholm University. She has 28 years of experience from Pharmaceutical Development and CMC Regulatory Affairs working for AstraZeneca, Galderma and Medivir. Her experience covers biotech products, small molecules, medical devices and cosmetics from early to late stage development through to commercial manufacturing.
Head of Business Development
Xiaoli has a Medical Doctor degree from Shanghai Jiao Tong University as well as a Ph.D in Medical Science from Karolinska Institutet. Xiaoli has experience in business development from the pharmaceutical industry, most recently as Head of Business Development at Affibody, where she led the work on the commercial partnership agreement of USD 650 million with Alexion and the co-development agreement with GE Healthcare. Prior to that, Xiaoli spent almost four years on HealthCap, a leading Nordic health and healthcare investor.